DiscGenics Study Updates: Injectable Discogenic Cell Therapy

DiscGenics completed enrollment in its Japanese safety study of allogeneic, injectable discogenic cell therapy (IDCT).

This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.


document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us